AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma
AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.
